IHC - Breast Hormone Receptor and Prognostic Panel

The test is performed to determine the presence and levels of specific markers in breast cancer cells. This information helps your doctor make an accurate diagnosis, predict how aggressive the cancer might be, and decide the most effective treatment plan.

No, fasting is not required before this test as it uses tissue samples, not blood samples.

The test is typically recommended after a diagnosis of breast cancer to help characterize the tumor and determine the most appropriate treatment.

This test measures the presence and level of four key markers in breast cancer cells - Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2Neu), and Ki67.

This test is typically performed at the time of diagnosis to determine the characteristics of the tumor. Depending on the situation, it might be repeated if there is recurrence or if the nature of the tumor seems to have changed.

The interpretation of the results depends on the type of cancer and the specific markers. Your doctor will discuss the results with you in relation to your specific situation.

No specific precautions are needed before or after this test. However, you should follow your doctor's advice regarding the biopsy or surgery that provides the tissue sample.

Several factors can influence the levels of these markers, including the type and stage of cancer, menopausal status, and individual genetic factors. It's important to discuss these factors with your doctor.

You should consult with a medical oncologist, who specializes in treating cancer with medications, including chemotherapy.

No, this test requires a tissue sample that needs to be obtained in a medical setting, and the analysis should be performed in a specialized laboratory.

Modifiable factors that may affect these markers include body weight, physical activity, and alcohol consumption. Studies suggest that maintaining a healthy weight, regular exercise, and moderating alcohol intake can influence the biology of breast tumors.

Non-modifiable factors that can influence these markers include age, genetics, and menopausal status. For instance, the likelihood of having hormone receptor-positive breast cancer increases with age and it is often higher in postmenopausal women.

The results of this test play a crucial role in deciding your treatment plan. For example, if your cancer is ER or PR positive, hormonal therapies may be effective. If it is HER2Neu positive, targeted therapies might be chosen. If Ki67 levels are high, it indicates a more aggressive tumor and may lead to a more intensive treatment approach.

The pain associated with this test is not from the test itself, but from the procedure used to collect the tissue sample. You might feel discomfort or slight pain during the biopsy, but your healthcare provider will use local anesthesia to minimize any discomfort.

The test itself poses no risks. However, there may be slight risks associated with the biopsy or surgical procedure used to collect the tissue sample, such as infection, bleeding, or an adverse reaction to anesthesia. Your doctor will discuss these potential risks with you prior to the procedure.

Understanding your breast cancer at the molecular level through tests like the IHC - Breast Hormone Receptor and Prognostic Panel (ER, PR, HER2Neu, Ki67) can play a vital role in personalizing your treatment plan. This can ensure you receive the most effective therapies for your specific type of cancer. Always remember, every step taken in diagnosing and treating your cancer, including this test, is bringing you one step closer to recovery. If you have any further questions, please consult your healthcare provider.